MRI-guided Bone Marrow Biopsies of Advanced CaP Patients
30 Years
N/A
Male
Prostate Cancer
Trial Information
MRI-guided Bone Marrow Biopsies of Advanced CaP Patients
- This study involves a one-time, MRI-guided bone marrow biopsy. Prior to this
procedure, patients will need to have a bone scan performed within the last three
months and a PSA blood test drawn within one month of registration to the study.
- Patients are also required to participate in the DFCI research study "Collection of
Specimens and Clinical Data for Patients with Prostate Cancer or at High Risk for
Prostate Cancer".
Inclusion Criteria:
- Histologic diagnosis of prostate cancer
- Bone scan consistent with or suspicious of metastatic prostate cancer within last
three months
- Platelet count > 50,000/ul
- PT and aPTT < 1.5 x control
- At least one week removed from taking aspirin or coumadin
- Currently participating in protocol "Collection of Specimens and Clinical Data for
Patients with Prostate Cancer or at High Risk for Prostate Cancer"
Exclusion Criteria:
- Devices incompatible to MR studies (e.g. pacemakers, ear implants, etc.)
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
To compare the yield of detecting metastatic prostate cancer tissue using MRI-guided bone marrow needle biopsies to that of historical controls obtained through unguided biopsies.
Principal Investigator
Mary-Ellen Taplin, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Dana-Farber Cancer Institute
Authority:
United States: Institutional Review Board
Study ID:
01-108
NCT ID:
NCT00165386
Start Date:
July 2001
Completion Date:
January 2006
Related Keywords:
- Prostate Cancer
- MRI-guided bone marrow biopsy
- Prostatic Neoplasms
Name | Location |
|---|---|
| Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
